The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara ...

Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara ...

LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The clinical hold by the FDA is on active investigational new drug applications for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) treatment Ebvallo ...

It closed at $6.93 on Jan. 23. Preceding the sharp decline was the Food and Drug Administration releasing a letter to the company stating concerns about the third-party manufacturer of its blood ...

This decision comes in the wake of the Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding Atara's EBVALLO application and the subsequent halt of several clinical trials.

UU. (FDA) sobre la solicitud de EBVALLO de Atara y la posterior suspensión de varios ensayos clínicos. Según la empresa, se espera que la reducción de plantilla se complete en gran medida para ...

Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

According to the Company, “The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO.” The FDA took the ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO." If you are a shareholder ...